Send us Feedback

Accentia Biopharmaceuticals (ABPI)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
STOCK CHART
Financials
SEC FILINGS

 
Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Mar 7, 2013)
  • 8-K (Feb 22, 2013)
  • 8-K (Nov 23, 2012)
  • 8-K (Oct 15, 2012)
  • 8-K (Aug 14, 2012)
  • 8-K (Jun 21, 2012)

 
Other

Accentia Biopharmaceuticals 8-K 2012

Documents found in this filing:

  1. 8-K
  2. 8-K
FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 29, 2012

 

 

ACCENTIA BIOPHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Florida   000-51383   04-3639490

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

(Address of Principal Executive Offices; Zip Code)

Registrant’s telephone number, including area code: (813) 864-2554

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ACCENTIA BIOPHARMACEUTICALS, INC.

FORM 8-K

 

Item 5.02. Compensatory Arrangements of Certain Officers.

On February 29, 2012, the Board of Directors of Accentia Biopharmaceuticals, Inc. (the “Company”) approved the following compensation arrangements for the below-named officers as a result of an annual compensation review by the Board of Directors and its Compensation Committee. However, such arrangements will be contingent on, and not commence until, the Company and its majority-owned subsidiary, Biovest International, Inc. has raised at least an aggregate cumulative total of $4.0 million in new financing:

 

  •  

Francis E. O’Donnell, Jr. M.D., the Company’s Executive Chairman will receive an increase to his base salary from $1.00 to $74,379 per year and a cash bonus of $38,150 for fiscal year ending September 30, 2012.

 

  •  

Garrison J. Hasara, CPA, the Company’s Acting Chief Financial Officer and Controller will receive an increase to his base salary from $181,342 to $196,342 per year. He will receive an additional $15,000 base salary increase if he becomes the Company’s Chief Financial Officer when the Board of Director considers such matter later in the year.

 

  •  

Samuel S. Duffey, Esq., the Company’s President and Chief Executive Officer, will receive an increase to his base salary from $206,321 to $212,511 per year and a cash bonus of $109,000 for fiscal year ending September 30, 2012.

In addition to the foregoing, on February 29, 2012, the Company granted stock options to purchase the following number of shares of the Company’s common stock: Dr. O’Donnell (300,000 shares), Mr. Duffey (600,000 shares), and Mr. Hasara (100,000 shares). Such options were granted under the Company’s 2010 Equity Incentive Plan at an exercise price of $0.44 per share and immediately vested upon the grant date.

 

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ACCENTIA BIOPHARMACEUTICALS, INC.
By:  

/s/ Samuel S. Duffey

  Samuel S. Duffey, Esq.
  Chief Executive Officer, President and General Counsel

Date: March 6, 2012

 

3

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki